Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	43.05	65.47	112.35	4.32	3.56
Short-Term Investments	24.69	17.38	0	0	0
Cash & Cash Equivalents	67.74	82.85	112.35	4.32	3.56
Cash Growth	-18.24%	-26.26%	2499.40%	21.58%	-84.11%
Receivables	17.38	8.3	1.53	2.58	1.87
Inventory	9.84	0.67	0	0	0
Other Current Assets	-8.02	1.02	1.18	1.48	1.55
Total Current Assets	86.94	92.83	115.06	8.38	6.97
Property, Plant & Equipment	1.53	1.78	2.03	2.39	3.01
Long-Term Investments	0	20	15.42	0	0
Goodwill and Intangibles	73.93	0	0	0	0
Other Long-Term Assets	9.94	0.72	0.44	0.44	0.53
Total Long-Term Assets	85.39	22.51	17.89	2.83	3.54
Total Assets	172.33	115.34	132.94	11.21	10.51
Accounts Payable	28.4	6.17	3.04	6.65	4.91
Deferred Revenue	12.21	8.98	0	0	0
Current Debt	38.24	0.48	0.36	0.72	0.28
Other Current Liabilities	-5.14	-3.61	0.84	0.17	0.24
Total Current Liabilities	73.72	12.02	4.23	7.54	5.43
Long-Term Debt	5.52	13.64	1.23	69.64	79.24
Other Long-Term Liabilities	31.22	14.55	0.36	0.45	0.29
Total Long-Term Liabilities	36.74	28.2	1.59	70.09	79.53
Total Liabilities	110.46	40.22	5.82	77.62	84.96
Total Debt	43.77	14.12	1.59	70.35	79.53
Debt Growth	209.88%	789.36%	-97.74%	-11.54%	-3.07%
Retained Earnings	-399.78	-353.73	-267.03	-258.47	-245.71
Comprehensive Income	-0.04	0.11	0	0	0
Shareholders' Equity	61.86	75.12	127.12	-66.41	-74.46
Net Cash / Debt	23.97	68.72	110.76	-66.03	-75.97
Net Cash / Debt Growth	-65.12%	-37.95%	-	-	-
Net Cash Per Share	0.68	1.99	3.72	-16.59	-40.99
Working Capital	13.22	80.81	110.83	0.85	1.54
Book Value Per Share	1.75	2.18	4.27	-16.68	-40.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).